Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 83 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Influenza A, Influenza B Clear all
Completed Not applicable Interventional

Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.

NCT05354115
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
14 Years to 100 Years
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Easley, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 6, 2026, 2:31 AM EDT
Completed No phase listed Observational Results available

Collection and Testing of Respiratory Samples

NCT01302418
View directory record Official record
Conditions
QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions
artus Influenza A/B RT-PCR Test
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
Not listed
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device

NCT05715515
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
Panbio™
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
Not listed
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Easley, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 6, 2026, 2:31 AM EDT
Suspended Phase 3 Interventional

Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B

NCT00828100
View directory record Official record
Conditions
Influenza
Interventions
fluID Rapid Influenza Test, BinaxNOW® Influenza A & B
Device
Lead sponsor
Nanogen, Inc.
Industry
Eligibility
Not listed
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Shreveport, Louisiana • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 6, 2009 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Clinical Performance of the Diassess Influenza A and B Test

NCT03035396
View directory record Official record
Conditions
Influenza, Human, Influenza, Flu
Interventions
Diassess Influenza A and B Test
Device
Lead sponsor
Diassess Inc.
Industry
Eligibility
Not listed
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 6, 2026, 2:31 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AV0328 Administered to Healthy Adult Volunteers

NCT02853617
View directory record Official record
Conditions
PNAG-expressing Pathogenic Microbes Vaccine
Interventions
AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3, AV0328 - Cohort 4
Biological
Lead sponsor
Alopexx Vaccine, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

NCT01014988
View directory record Official record
Conditions
Influenza, Human
Interventions
zanamivir aqueous solution
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

NCT02287467
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00835926
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Impact of Rapid Flu Testing in BMC ED

NCT02979730
View directory record Official record
Conditions
Influenza-Like Illness, Influenza
Interventions
Core Lab Test, ED Point of Care Test
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

NCT02214225
View directory record Official record
Conditions
Influenza, Human
Interventions
Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
33
States / cities
Huntsville, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 6, 2026, 2:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

T and B Cell Response to Avian Flu Vaccine

NCT00337896
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

NCT00192192
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

NCT01246999
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV
Biological
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 9 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

NCT05630365
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
Panbio™
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
Not listed
Enrollment
1,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 6, 2026, 2:31 AM EDT
Completed No phase listed Observational

Project STARFISH - PRJ0002679

NCT05727202
View directory record Official record
Conditions
SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
Interventions
The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
Diagnostic Test
Lead sponsor
Thermo Fisher Scientific, Inc
Industry
Eligibility
Not listed
Enrollment
1,909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
17
States / cities
San Diego, California • Lake City, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

NCT01250795
View directory record Official record
Conditions
Healthy
Interventions
HAI-05 Influenza Vaccine, Saline
Biological · Other
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Wichita, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI

NCT06229444
View directory record Official record
Conditions
Influenza, Influenza A, Influenza B, COVID-19, Respiratory Syncytial Virus (RSV)
Interventions
ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content, No Intervention
Behavioral
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
17,043 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 6, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

NCT03969212
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 64 Years
Enrollment
4,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 6, 2026, 2:31 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT01924169
View directory record Official record
Conditions
Hematologic Disorder
Interventions
Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 6, 2026, 2:31 AM EDT
Completed No phase listed Observational

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

NCT06008457
View directory record Official record
Conditions
COVID-19 Respiratory Infection, Influenza A, Influenza Type B, RSV Infection
Interventions
Labcorp COVID-19+Flu+RSV Test Home Collection Kit
Device
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
2 Years to 89 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 6, 2026, 2:31 AM EDT